Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males
NCT ID: NCT07076771
Last Updated: 2025-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2025-01-01
2025-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients
NCT07154186
Correlation Between Serum Copper and Cardiac Enzymes in Acute Myocardial Infarction
NCT07076758
Premature Coronary Artery Disease and Familial Dyslipidemia in Patients Presenting With Acute Coronary Syndrome
NCT07267312
Relationship Between Heme Oxygenase 1 Enzyme Level and Coronary SYNTAX Score
NCT04070014
Value of Triglyceride Glucose Index in Prediction of Cardiac Outcomes in Patients With Acute Coronary Syndrome
NCT05158231
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Testosterone, the primary male sex hormone, exerts various physiological effects beyond its role in reproductive function. It influences muscle mass, fat distribution, insulin sensitivity, and vascular tone. Low testosterone levels have been associated with adverse metabolic profiles, including increased adiposity, dyslipidemia, and insulin resistance, all of which are established risk factors for atherosclerosis. Furthermore, testosterone deficiency has been linked to endothelial dysfunction, a critical early event in the development of atherosclerotic plaques.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Significant coronary artery disease (CAD) group
Patients with significant coronary artery disease
Coronary Angiography
All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.
Syntax Score
The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.
Non-significant coronary artery disease (CAD) group
Patients with non-significant coronary artery disease
Coronary Angiography
All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.
Syntax Score
The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coronary Angiography
All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.
Syntax Score
The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with premature ischemic heart disease.
* Undergoing elective coronary angiography for suspected coronary artery disease (CAD) .
Exclusion Criteria
* Prior diagnosis of hypogonadism or history of testosterone replacement therapy or anabolic steroid use.
* Active neoplasm or history of chemotherapy.
* Known hepatic cirrhosis, chronic kidney disease, or end-stage renal disease.
* Use of medications known to affect sex hormone levels (e.g., spironolactone, ketoconazole).
* Endocrine disorders such as sickle cell anemia or celiac disease.
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Remon Saleh Adly
Lecturer of Cardiovascular, Faculty of Medicine, Sohag University, Sohag, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-25-5-9PD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.